Genomic diagnostics company making tests that help diagnose thyroid, lung, prostate and other cancers from tissue samples.
Genomic diagnostics company making tests that help diagnose thyroid, lung, prostate and other cancers from tissue samples.
Is paid per test: samples go to its own labs, which report a result, and Medicare and private insurers reimburse them, so coverage decisions matter as much as clinical results. The Afirma thyroid test has long been the base, with prostate and lung tests widening it.
Moat: narrow (IP / patents, data, regulatory licence). Proprietary genomic classifiers built on large clinical datasets are costly for rivals to replicate and validate.
Headquarters: South San Francisco, California · Founded: 2008 · Employees: 755
Size Veracyte (VCYT) is a United States Health Care company (Medical Specialties) with a market value of $2.06B, the 1753rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $25.57 on 18 Nov 2026.
Performance Over six months the shares fell 43.4%, against +3.5% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd lowest of 20 in its peer set.
Growth Revenue grew 17.5% over the last twelve months (peer median +7.9%); the operating margin is 15.5% (peer median 16.2%).
Valuation It trades at 17.1× forward earnings against a peer median of 24.3× (6th cheapest of 19).
Price implies For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +35%, so the hurdle is -17 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 8.3 points below its cost of capital (14.8% WACC).
Short interest Short interest is 11.8% of the free float (30 Oct 2026).
Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $582M | $517M | $446M | $361M | $297M |
| Revenue growth | — | +16% | +23% | +22% | — |
| Gross profit | $417M | $355M | $290M | $223M | $171M |
| EBITDA | $112M | $115M | $56.7M | $15.1M | -$8.36M |
| Net income | $127M | $66.4M | $24.1M | -$74.4M | -$36.6M |
| Free cash flow | $162M | $127M | $63.8M | $34.3M | -$1.01M |
| Capital expenditure | $11.9M | $9.68M | $11.3M | $9.96M | $8.55M |
| Total debt | $40.7M | $39.7M | $50.7M | $12.6M | $14.7M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Veracyte VCYT | $2.06B | -43% | +18% | 16% | 17.1× | 18.0% |
| Myriad Genetics MYGN | $530M | +45% | -3% | -13% | n/a | n/a |
| Natera NTRA | $42.0B | +41% | +37% | -9% | n/a | n/a |
| Guardant Health GH | $19.6B | +26% | +42% | -39% | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | VCYT | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -42.9% | +1.9% | lowest of 21 |
| 6-month return | -43.4% | +3.5% | 2nd lowest of 20 |
| Distance from 52-week high | -58.0% | -11.5% | 2nd lowest of 21 |
| Revenue growth (TTM) | +17.5% | +7.9% | 6th highest of 21 |
| Operating margin | 15.5% | 16.2% | 10th lowest of 21 |
| Forward P/E | 17.1× | 24.3× | 6th cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | 18.0% | 9.2% | 4th most demanding of 15 |
| Growth delivered (Del g) | +34.5% | +11.1% | 2nd highest of 15 |
| Hurdle (Req g minus delivered) | -16.5 pp | -1.7 pp | 2nd least demanding of 15 |
| ROIC minus cost of capital | -8.3 pp | +3.5 pp | 3rd lowest of 21 |
| EV / EBITDA | 15.5× | 18.1× | 6th cheapest of 16 |
| Net debt / EBITDA | -3.0× | -0.8× | least indebted of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Veracyte VCYT | United States | $2.06B | -43% | +18% | 16% | 17.1× | 18.0% | +34.5% |
| Bonesupport BONEX.ST | Sweden | $2.06B | +21% | +25% | 25% | 61.5× | 12.6% | +45.4% |
| Establishment Labs ESTA | United States | $2.11B | +1% | +38% | -7% | n/a | n/a | n/a |
| JEOL 6951.T | Japan | $2.12B | -2% | -15% | 12% | 15.5× | 22.2% | +10.2% |
| Draegerwerk AG & Co. KGaA DRW8.DE | Germany | $2.13B | +25% | +5% | 7% | 10.2× | -10.2% | +0.4% |
| Metall Zug METN.SW | Switzerland | $2.19B | +20% | 0% | -10% | 139.8× | n/a | n/a |
| Shanghai Conant Optical 2276.HK | Hong Kong | $2.25B | -17% | +8% | 29% | 22.1× | -1.1% | +14.1% |
| Medartis MED.SW | Switzerland | $1.86B | +47% | +30% | 2% | 72.8× | n/a | n/a |
| SKAN SKAN.SW | Switzerland | $1.85B | +40% | +9% | 11% | 49.5× | 13.8% | +11.7% |
| Molbio Diagnostics MOLBIO.NS | India | $1.85B | n/a | +35% | 17% | n/a | n/a | n/a |
| Rigaku 268A.T | Japan | $1.85B | -54% | +9% | 16% | 23.1× | 18.3% | +14.5% |
| Fukuda Denshi 6960.T | Japan | $1.84B | +4% | 0% | 19% | 15.4× | -1.6% | -1.0% |
| Micro-Tech (Nanjing) 688029.SS | China | $2.33B | 0% | +6% | 18% | 28.1× | 11.9% | +19.2% |
| Shandong Weigao Group Medical Polymer 1066.HK | Hong Kong | $1.82B | -8% | +7% | 14% | 8.2× | -12.6% | +2.1% |
| Elekta EKTA-B.ST | Sweden | $2.35B | 0% | -7% | 6% | 15.3× | 10.7% | +4.0% |
| Jafron Biomedical 300529.SZ | China | $2.35B | +3% | +1% | 37% | 24.3× | 6.1% | +0.6% |
| Poly Medicure POLYMED.NS | India | $1.79B | +14% | +25% | 16% | 39.9× | n/a | n/a |
| Nakanishi 7716.T | Japan | $1.78B | +7% | +17% | 21% | 19.0× | 4.8% | +19.7% |
| ChemoMetec A/S CHEMM.CO | Denmark | $1.77B | +107% | +3% | 49% | 46.7× | 19.4% | +12.7% |
| Neogen NEOG | United States | $2.42B | +25% | 0% | 0% | 32.6× | n/a | n/a |
| Double Medical Technology 002901.SZ | China | $2.43B | -2% | +13% | 26% | 24.2× | 7.6% | +10.4% |